68Ga-NeoB PET/CT在雌激素受体和孕激素受体阳性乳腺癌分期或再分期中的诊断潜力
本研究前瞻性纳入20例ER/PR阳性且HER2阴性、临床怀疑转移的乳腺癌患者,同时行68Ga-NeoB PET/CT与标准18F-FDG PET/CT。视觉评估显示68Ga-NeoB PET/CT阳性率为75%(15/20),18F-FDG PET/CT为65%(13/20);定量中位SUVmax分别为20.5和7.4。结论认为68Ga-NeoB PET/CT在ER/PR阳性、HER2阴性乳腺癌分期中具有诊断潜力,需进一步评估。
要点
- 20例ER/PR阳性HER2阴性乳腺癌患者中,68Ga-NeoB PET/CT视觉阳性率75%(15/20),18F-FDG PET/CT为65%(13/20)。
- 分期组68Ga-NeoB阳性75%(6/8)vs 18F-FDG阳性50%(4/8);再分期组两者均为75%(9/12 vs 9/12)。
- 68Ga-NeoB PET/CT中位SUVmax 20.5(IQR 5.8-31.3)高于18F-FDG PET/CT的7.4(IQR 4.9-9.8)。
核心结论
- 68Ga-NeoB PET/CT在ER/PR阳性且HER2阴性乳腺癌的分期中具有诊断潜力,需进一步评估。
研究设计与样本
- 前瞻性纳入临床怀疑转移、拟行分期或再分期的ER/PR阳性且HER2阴性乳腺癌患者20例,均行68Ga-NeoB PET/CT和标准18F-FDG PET/CT。
- ER/PR阳性且HER2阴性状态经既往活检样本(原发或转移灶)确认,常规影像(18F-FDG PET/CT、骨扫描和诊断性CT)需在68Ga-NeoB PET/CT前3周内完成。
- 所有扫描由2名阅片者盲法视觉评估,结果不一致时由第3名阅片者判定,并进行定量评估。
主要发现
- 75%(15/20)的患者68Ga-NeoB PET/CT视觉评估为阳性,65%(13/20)的患者18F-FDG PET/CT为阳性。
- 50%(10/20)的患者两种扫描均阳性,10%(2/20)的患者两种扫描均阴性。
- 分期组中,68Ga-NeoB PET/CT阳性75%(6/8),18F-FDG PET/CT阳性50%(4/8);再分期组中,两者阳性率均为75%(9/12 vs 9/12)。
- 68Ga-NeoB PET/CT阳性而18F-FDG PET/CT阴性的病灶见于50%(4/8)的分期患者和42%(5/12)的再分期患者。
- 68Ga-NeoB PET/CT阴性而18F-FDG PET/CT阳性的病灶见于0例分期患者和58%(7/12)的再分期患者,其中71%(5/7)的患者最近一次活检样本中ER状态降低。
局限性
- 原文结论指出需进一步评估(Further evaluation is warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-FDG PET/CT has low sensitivity for estrogen receptor and progesterone receptor (ER/PR)-positive breast cancer. By contrast, gastrin-releasing peptide receptor is overexpressed in ER/PR-positive breast cancer. This study assessed the diagnostic potential of 68Ga-NeoB PET/CT in staging or restaging metastatic ER/PR-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Patients with ER/PR-positive and HER2-negative breast cancer with clinical suspicion for metastatic disease undergoing staging or restaging were prospectively enrolled. All patients underwent 68Ga-NeoB PET/CT, in addition to standard 18F-FDG PET/CT. ER/PR-positive and HER2-negative status was confirmed in prior biopsy samples (primary or metastatic). Conventional imaging (18F-FDG PET/CT, bone scan, and diagnostic CT) was required within 3 wk of 68Ga-NeoB PET/CT. 18F-FDG PET/CT and 68Ga-NeoB PET/CT were assessed visually and quantitatively. Visually, all scans were read masked by 2 readers, with a third reader if results were discordant. Results: Twenty patients were enrolled, all with ER/PR-positive and HER2-negative histopathology. Of these, 75% (15/20) had lobular-subtype cancer, 40% (8/20) had suspected metastatic disease at diagnosis, and 60% (12/20) underwent restaging after systemic therapy. Overall, 75% (15/20) of the 68Ga-NeoB PET/CT scans and 65% (13/20) of the 18F-FDG PET/CT scans were positive on visual assessment. For 50% (10/20) of patients, both scans were positive, and for 10% (2/20) of patients, both scans were negative. In the staging group, 75% (6/8) of patients had positive 68Ga-NeoB PET/CT and 50% (4/8) of patients had positive 18F-FDG PET/CT. At restaging, 75% (9/12) of patients had positive 68Ga-NeoB PET/CT and 75% (9/12) of patients had positive 18F-FDG PET/CT. Sites of positive 68Ga-NeoB PET/CT and negative 18F-FDG PET/CT disease were identified in 50% (4/8) of staging patients and 42% (5/12) of restaging patients, whereas negative 68Ga-NeoB PET/CT and positive 18F-FDG PET/CT disease was found in none of the staging patients but 58% (7/12) of the restaging cohort. Of these, 71% (5/7) of patients had a reduction in their ER status in the most recent biopsy samples. Quantitatively, the median SUVmax was higher for 68Ga-NeoB PET/CT (20.5; interquartile range, 5.8-31.3) than for 18F-FDG PET/CT (7.4; interquartile range, 4.9-9.8). Conclusion: 68Ga-NeoB PET/CT has diagnostic potential in the staging of ER/PR-positive and HER2-negative breast cancer. Further evaluation is warranted.
引用
- Sabahi Z, Nguyen A, Wong K, et al. Diagnostic Potential of 68Ga-NeoB PET/CT with Estrogen Receptor- and Progesterone Receptor-Positive Breast Cancer Undergoing Staging or Restaging for Metastatic Disease. J Nucl Med. 2025. PMID: 40147847. doi:10.2967/jnumed.124.268896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。